Abbott Laboratories $ABT Shares Purchased by StrongBox Wealth LLC

StrongBox Wealth LLC increased its position in shares of Abbott Laboratories (NYSE:ABT) by 33.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,538 shares of the healthcare product maker’s stock after purchasing an additional 10,845 shares during the quarter. Abbott Laboratories accounts for 1.8% of StrongBox Wealth LLC’s investment portfolio, making the stock its 21st biggest holding. StrongBox Wealth LLC’s holdings in Abbott Laboratories were worth $5,455,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC purchased a new stake in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the 3rd quarter valued at about $31,000. Delos Wealth Advisors LLC purchased a new stake in Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new stake in Abbott Laboratories during the third quarter valued at about $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.6%

Shares of ABT opened at $102.30 on Tuesday. The stock’s 50-day moving average is $109.35 and its two-hundred day moving average is $120.71. The stock has a market cap of $178.16 billion, a PE ratio of 27.50, a P/E/G ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 12 month low of $100.88 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Activity at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 over the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Daiwa Securities Group lowered their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Piper Sandler lowered their price target on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Evercore lowered their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Raymond James Financial lowered their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Citigroup lowered their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.68.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.